Galectin Therapeutics, Inc. (GALT) Skyrocketed to $4.68 on Apr, 7

April 7, 2018 - By Maria Robertson

Big Money Sentiment decreased to 0.53 in Q4 2017. It has 0.14, from change from 2017Q3’s 0.67. The ratio fall due to Galectin Therapeutics, Inc. positioning: 6 sold and 13 reduced. 7 funds took positions and 3 increased positions. Investors holded 3.22 million in 2017Q3 but now own 3.08 million shares or 4.50% less.
Norris Perne & French Limited Liability Partnership Mi stated it has 30,500 shs or 0.01% of all its holdings. Royal Savings Bank Of Canada invested 0% of its capital in Galectin Therapeutics, Inc. (NASDAQ:GALT). Courage Capital Management Ltd invested in 50,000 shs. Geode Mgmt Limited Co accumulated 195,411 shs. Riggs Asset Managment invested 0% of its capital in Galectin Therapeutics, Inc. (NASDAQ:GALT). Tci Wealth, a Arizona-based fund reported 300 shs. Fincl Bank Of New York Mellon Corporation stated it has 19,930 shs or 0% of all its holdings. Salem Invest Counselors stated it has 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). Morgan Stanley holds 16,168 shs. Sei Invs holds 0% or 3,800 shs. New York-based Art Advisors Limited Liability has invested 0.01% in Galectin Therapeutics, Inc. (NASDAQ:GALT). First Republic Investment Mngmt Incorporated holds 0% of its capital in Galectin Therapeutics, Inc. (NASDAQ:GALT) for 26,000 shs. 10,390 are held by Guggenheim Capital Limited Liability Com. Goldman Sachs Grp accumulated 0% or 12,528 shs. Buckingham Asset Mgmt Lc accumulated 10,000 shs or 0.01% of the stock.

Galectin Therapeutics, Inc. registered $2.64 million net activity with 2 insider purchases and 2 sales since January 25, 2018. On Thursday, February 1 a trade for 2,000 shs valued at $8,191 was made by FREEMAN KEVIN D. $1.33M worth of stock was sold by 10X Fund – L.P. on Thursday, January 25.

Galectin Therapeutics, Inc. (NASDAQ:GALT) increased to $4.68. It was reported on Apr, 7 according to Barchart.com The company has $175.83M market cap. $8.79M more could be NASDAQ:GALT valuation at $4.91 share price.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer.The company has $175.83 million market cap. The companyÂ’s lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer.Currently it has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Let's block ads! (Why?)

Bagikan Berita Ini